Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
National Institute of Cardiovascular Research, Bologna, Italy.
Curr Med Chem. 2020;27(2):230-239. doi: 10.2174/0929867326666190325094453.
The incidence of obesity and diabetes is increasing rapidly worldwide. Obesity and metabolic syndrome are strictly linked and represent the basis of different cardiovascular risk factors, including hypertension and inflammatory processes predisposing to ischemic heart disease, which represent the most common causes of heart failure. Recent advances in the understanding of ischemia/reperfusion mechanisms of injury and mechanisms of cardioprotection are briefly considered. Resistance to cardioprotection may be correlated with the severity of obesity. The observation that heart failure obese patients have a better clinical condition than lean heart failure patients is known as "obesity paradox". It seems that obese patients with heart failure are younger, making age the most important confounder in some studies. Critical issues are represented by the "obesity paradox" and heart failure exacerbation by inflammation. For heart failure exacerbation by inflammation, an important role is played by NLRP3 inflammasome, which is emerging as a possible target for heart failure condition. These critical issues in the field of obesity and cardiovascular diseases need more studies to ascertain which metabolic alterations are crucial for alleged beneficial and deleterious effects of obesity.
肥胖和糖尿病的发病率在全球范围内迅速上升。肥胖和代谢综合征密切相关,是多种心血管危险因素的基础,包括高血压和易导致缺血性心脏病的炎症过程,这是心力衰竭最常见的病因。简要考虑了缺血/再灌注损伤机制和心脏保护机制的最新研究进展。对心脏保护的抵抗力可能与肥胖的严重程度相关。肥胖心力衰竭患者的临床状况优于瘦弱心力衰竭患者的观察结果被称为“肥胖悖论”。似乎心力衰竭肥胖患者更年轻,年龄是某些研究中最重要的混杂因素。关键问题是“肥胖悖论”和炎症引起的心力衰竭恶化。炎症引起的心力衰竭恶化,NLRP3 炎性小体起着重要作用,它正成为心力衰竭的一个可能治疗靶点。肥胖和心血管疾病领域的这些关键问题需要更多的研究来确定哪些代谢改变对肥胖的所谓有益和有害影响至关重要。